Alexion to acquire Achillion
Alexion and Achillion announced an agreement for Alexion to acquire Achillion, a clinical-stage biopharmaceutical company focused on the development of oral small molecule Factor D inhibitors. The initial consideration of approximately $930 million, or $6.30 per share of Achillion common stock. October 16, 2019